Depo-Provera

Endometrial Hyperplasia, Endometriosis, Chronic Pain + 18 more

Treatment

7 FDA approvals

20 Active Studies for Depo-Provera

What is Depo-Provera

Medroxyprogesterone acetate

The Generic name of this drug

Treatment Summary

Medroxyprogesterone acetate (MPA) is a hormone-based drug that was approved by the FDA in 1959. Its main purpose is to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, and osteoporosis. It can also be used to reduce pain in endometriosis, manage vasomotor symptoms in menopause, and prevent pregnancy. MPA is also used to treat endometrial and renal carcinoma in palliative care.

Medroxyprogesterone Acetate

is the brand name

image of different drug pills on a surface

Depo-Provera Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Medroxyprogesterone Acetate

Medroxyprogesterone acetate

1959

139

Approved as Treatment by the FDA

Medroxyprogesterone acetate, also known as Medroxyprogesterone Acetate, is approved by the FDA for 7 uses such as Vasomotor Symptoms Associated With Menopause and Vulvo Vaginal Atrophy .

Vasomotor Symptoms Associated With Menopause

Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens

Vulvo Vaginal Atrophy

Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens

Postmenopausal Osteoporosis

Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens

Hot flashes

Used to treat Menopause in combination with Conjugated estrogens

Hot Flashes

Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens

Osteoporosis, Postmenopausal

Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens

Atrophic

Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens

Effectiveness

How Depo-Provera Affects Patients

Medroxyprogesterone acetate, or MPA, blocks hormones that help cells grow and can cause cell death in cancer cells. Depending on the form of MPA taken, its effects can last for up to a week. The drug is available in doses from 5mg daily to 1000mg a week, so it can be taken in a variety of ways. Unfortunately, long-term use of MPA can reduce bone density and lead to osteoporosis and fractures in the future - especially if taken during adolescence.

How Depo-Provera works in the body

Medroxyprogesterone acetate (MPA) works to prevent pregnancy by stopping the release of hormones that cause ovulation. It also thins the lining of the uterus. MPA reduces estrogen receptors in the endometrium, and can induce apoptosis in some cancer cell lines. It also works to inhibit certain GABA-A receptors.

When to interrupt dosage

The prescribed dosage of Depo-Provera is contingent upon the diagnosed condition, for example Hormonal Contraception, Amenorrhea and Postmenopausal Osteoporosis. The level of dosage is contingent upon the mode of administration (e.g. Tablet - Oral or Intramuscular) stated in the table hereunder.

Condition

Dosage

Administration

Endometriosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Chronic Pain

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Amenorrhea

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Osteoporosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

conjugated estrogen

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

hypoestrogenism

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Birth Control

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Endometriosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Endometrial Neoplasms

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Fracture

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hot flashes

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Osteoporosis, Postmenopausal

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Estrogen Replacement Therapy

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hot Flashes

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Uterine hemorrhage

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Atrophic

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hormonal Contraception

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Kidney Neoplasms

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Pharmaceutical Preparations

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Pharmaceutical Preparations

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Warnings

Depo-Provera Contraindications

Condition

Risk Level

Notes

Thromboembolism

Do Not Combine

Breast

Do Not Combine

Thrombophlebitis

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Breast

Do Not Combine

Breast Cancer

Do Not Combine

Stroke

Do Not Combine

Vascular Diseases

Do Not Combine

Thromboembolism

Do Not Combine

Liver Disease

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

suspected pregnancy

Do Not Combine

Disease

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Medroxyprogesterone Acetate may interact with Pulse Frequency

There are 20 known major drug interactions with Depo-Provera.

Common Depo-Provera Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Medroxyprogesterone acetate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Medroxyprogesterone acetate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Medroxyprogesterone acetate.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Medroxyprogesterone acetate.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Medroxyprogesterone acetate.

Depo-Provera Toxicity & Overdose Risk

The lowest toxic dose of medroxyprogesterone acetate in rats is greater than 6400mg/kg and in mice is greater than 16g/kg. Overdosing on MPA can cause symptoms such as nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and vaginal bleeding. If someone has been given too much of a MPA depo injection, they should seek medical help immediately.

image of a doctor in a lab doing drug, clinical research

Depo-Provera Novel Uses: Which Conditions Have a Clinical Trial Featuring Depo-Provera?

406 active clinical trials are currently assessing the potential of Depo-Provera to provide Osteoporosis, Amenorrhea and Hormonal Contraception relief.

Condition

Clinical Trials

Trial Phases

Endometriosis

27 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Osteoporosis

27 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Chronic Pain

130 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1

Endometrial Neoplasms

0 Actively Recruiting

Fracture

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Pharmaceutical Preparations

0 Actively Recruiting

Birth Control

22 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Estrogen Replacement Therapy

0 Actively Recruiting

Hormonal Contraception

0 Actively Recruiting

Endometriosis

2 Actively Recruiting

Phase 4, Not Applicable

Hot Flashes

4 Actively Recruiting

Not Applicable, Phase 2, Phase 1

Kidney Neoplasms

35 Actively Recruiting

Phase 1, Phase 3, Phase 2, Not Applicable

conjugated estrogen

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

hypoestrogenism

1 Actively Recruiting

Phase 4

Atrophic

4 Actively Recruiting

Phase 4, Not Applicable

Amenorrhea

0 Actively Recruiting

Pharmaceutical Preparations

0 Actively Recruiting

Endometrial Hyperplasia

4 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Depo-Provera Reviews: What are patients saying about Depo-Provera?

5

Patient Review

8/26/2022

Depo-Provera for Endometriosis

This shot took some time to work for me, but it was well worth the wait. I have endometriosis and had already undergone surgery when I started this treatment. The first three months were tough with pain, bleeding, and mood swings, but after getting the second shot things really improved. Everyone is different, but don't expect this medication to fix all your problems in a month. Give it some chance to work its magic!

5

Patient Review

8/21/2022

Depo-Provera for Birth Control

I no longer have to deal with periods, which is amazing because they used to be really painful and heavy before I started this medication. They were affecting my iron levels as well, and since I already had anemia, I had to get four infusions of iron every week for weeks on end.

4.3

Patient Review

6/20/2022

Depo-Provera for Endometriosis

I've started taking depo to help with the pain and heavy bleeding I experience during my period. So far, I'm really pleased with it. I haven't had any side effects or bleed through since starting it a few weeks ago. Fingers crossed that it continues to go well!

4.3

Patient Review

9/24/2022

Depo-Provera for Birth Control

I've been on Depo-Provera for 11 years and, while there are some drawbacks like having to go to the doctor every 3 months and experiencing shakes, anxiety, heart palpitations, etc., I never have to worry about my period anymore. That being said, I am concerned about the bone loss that this is said to cause.

4

Patient Review

10/31/2022

Depo-Provera for Birth Control

I started the depo shot in September of 2021, and I was on it for over a year. Unfortunately, during that time I experienced extremely heavy and painful periods. Additionally, my sex drive plummeted while I was on this medication. Thankfully, I've since switched to the pill which has been much better for me.

3

Patient Review

10/17/2022

Depo-Provera for Birth Control

I gained a lot of weight while using this medication, but fortunately lost all of it after I stopped taking it. It was always very effective at preventing pregnancy, but the side effects were really terrible. I wouldn't recommend it to anyone.

2.7

Patient Review

9/1/2022

Depo-Provera for Birth Control

I started the depo shot on April 21st and experienced spotting every day for the next three months. I'm now in September and still haven't gotten my period back. This birth control method really messed up my body.

2.3

Patient Review

8/5/2022

Depo-Provera for Birth Control

I lost 20 pounds in 6 months while on the depo shot, but I started experiencing a whole host of other problems like PCOS, hair loss, anxiety, and depression. I stopped it a month ago and hope my health will improve.

2

Patient Review

1/31/2022

Depo-Provera for Birth Control

I was on my period for almost three weeks straight, which finally stopped last night. It was an incredibly difficult and frustrating experience; I felt dizzy, bloated, had mood swings, and low self-esteem the entire time. I would never get this shot again.

1

Patient Review

3/13/2022

Depo-Provera for Birth Control

I took the shot once and started experiencing weight gain, mood swings, and depression. My period also began about a week after taking it and I've been bleeding ever since--two periods a month, heavy and with daily spotting. If you're doubting whether or not to take this medication, trust your gut instinct.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about depo-provera

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Depo-Provera cause weight gain?

"Depot Provera (DMPA) is a commonly used and effective form of birth control, however, most studies confirm that weight gain is a common side effect for those who use it. DMPA is more likely to cause weight gain than other methods like the pill or an IUD."

Answered by AI

How long does Depo-Provera take to work?

"If you want to be protected from pregnancy as soon as possible, you should get your first birth control shot within the first 7 days after the start of your period. If you wait longer than that, it will take a full week for the shot to become effective. To be safe, you should use a backup method of contraception, like condoms, for the first week after getting the shot."

Answered by AI

What is the most common side effect of Depo-Provera?

"The shot can also make your periods lighter, heavier, or more frequent.

The birth control shot is most commonly associated with irregular bleeding. You may experience bleeding problems for 6 to 12 months after you first begin using the shot. The shot can also make your periods lighter, heavier, or more frequent."

Answered by AI

What does Depo do to your body?

"The Depo-Provera shot affects ovulation by preventing an egg from being released from a woman's ovary. It also thickens the cervical mucus, making it difficult for sperm to reach the egg."

Answered by AI

Clinical Trials for Depo-Provera

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Waitlist Available
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Have you considered Depo-Provera clinical trials?

We made a collection of clinical trials featuring Depo-Provera, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Have you considered Depo-Provera clinical trials?

We made a collection of clinical trials featuring Depo-Provera, we think they might fit your search criteria.
Go to Trials
Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Have you considered Depo-Provera clinical trials?

We made a collection of clinical trials featuring Depo-Provera, we think they might fit your search criteria.
Go to Trials